United States Viral Gene Therapy Market was valued at USD 3.50 Billion in 2022 and is projected to reach USD 8.83 Billion by 2030, growing at a CAGR of 12.3% from 2024 to 2030.
The Viral Gene Therapy Market in the United States is experiencing rapid growth, driven by advancements in biotechnology and a deeper understanding of genetic disorders. As of 2023, the U.S. gene therapy market was valued at approximately $3.11 billion and is projected to grow at a compound annual growth rate (CAGR) of 19.21% from 2024 to 2030. This surge is attributed to the increasing number of gene therapies entering clinical trials and receiving regulatory approvals.
Gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells to treat or prevent diseases. The primary types of gene therapy include:
Gene Augmentation Therapy: Introducing functional genes to compensate for nonfunctional ones.
Gene Silencing: Deactivating malfunctioning genes causing disease.
Gene Editing: Directly correcting genetic mutations at specific locations.
Viral vectors, such as lentivirus, adeno-associated virus (AAV), and adenovirus, are commonly used to deliver therapeutic genes into target cells. These vectors have been engineered to be safe and efficient, ensuring precise delivery of genetic material.
The industry has witnessed significant milestones in recent years. For instance, in 2023, CRISPR Therapeutics received approval for Casgevy, a gene therapy targeting sickle cell anemia and thalassemia, marking a pivotal moment in the application of CRISPR-Cas9 technology in clinical settings. Similarly, Sarepta Therapeutics introduced Elevidys for Duchenne muscular dystrophy, highlighting the potential of gene therapies to address previously untreatable conditions.
However, the commercialization of these therapies faces challenges. Despite their potential, treatments like those for sickle cell disease have seen slow patient uptake. Factors such as the high cost (ranging from $2 to $3 million), extensive procedures involving chemotherapy, and potential risks like infertility have made patients cautious. As of September 2024, only about 100 individuals globally had initiated these treatments, with stringent eligibility criteria limiting broader adoption.
Manufacturing complexities also pose significant hurdles. The production of gene therapies requires sophisticated facilities and stringent quality controls. Companies like Cellares are innovating in this space by developing automated production systems to streamline manufacturing processes, aiming to make these therapies more accessible and affordable.
From my experience in the biotech industry, I've observed that collaboration between academia, industry, and regulatory bodies is crucial. Initiatives like the partnership between Yale School of Medicine and the National Institutes of Health (NIH), which granted nearly $40 million to support the development of CRISPR-based gene therapies for genetic brain diseases, exemplify the collaborative efforts propelling the field forward.
In conclusion, the U.S. Viral Gene Therapy Market is on a promising trajectory, with advancements in vector development, regulatory approvals, and manufacturing innovations paving the way for broader therapeutic applications. However, addressing challenges related to cost, patient acceptance, and production scalability remains essential for the industry to realize its full potential.
Get an In-Depth Research Analysis of the US Viral Gene Therapy Market Size And Forecast [2025-2032]
Lonza
Biogen
Catalent
Gilead Sciences
Sarepta Therapeutics
Novartis
Amgen
Ionis Pharmaceuticals
Spark Therapeutics
Shanghai Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Viral Gene Therapy Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Viral Gene Therapy Market
Adenoviral Vectors
Retroviral Vectors
Adeno-Associated Viral Vectors (AAV)
Lentiviral Vectors
Other Viral Vectors
Oncolytic Viral Therapy
Gene Replacement Therapy
Gene Editing Therapy
Immunotherapy
Other Therapeutic Approaches
Oncology
Cardiovascular Diseases
Neurological Disorders
Genetic Disorders
Infectious Diseases
Other Applications
Hospitals and Clinics
Research Institutions
Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs)
In vivo Delivery
Ex vivo Delivery
Intravenous Route
Intramuscular Route
Intrathecal Route
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Viral Gene Therapy Market Research Analysis
1. Introduction of the US Viral Gene Therapy Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Viral Gene Therapy Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Viral Gene Therapy Market, By Type
6. US Viral Gene Therapy Market, By Application
7. US Viral Gene Therapy Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Viral Gene Therapy Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/